Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IRF7 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IRF7 Recombinant Protein (Full-Length / Active Domain) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for biochemical assays. |
View IRF7 Products |
| Gene Delivery | IRF7 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and reporter assays. |
View IRF7 Products |
| Benchmark Ab | Anti-IRF7 Recombinant Antibody High-affinity positive control for Western Blot, ELISA, and Flow Cytometry. |
View IRF7 Products |
| Validator | IRF7 siRNA Set Target-specific knockdown verification in human and murine cell lines. |
View IRF7 Products |
| Related Target A | TLR7 Upstream toll-like receptor driving IRF7 phosphorylation and Type I IFN production in pDCs. |
View TLR7 Products |
| Related Target B | TBK1 Critical kinase that phosphorylates and activates IRF7 downstream of STING/RLR pathways. |
View TBK1 Products |
| Related Target C | STING Central mediator of the cytosolic DNA sensing pathway upstream of IRF7 activation. |
View STING Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform & Homology Selectivity (IRF7 vs. IRF3) | Highly purified recombinant IRF7 and IRF3 proteins available for comparative cross-screening. |
| Phosphorylation-State Specificity | Sequence-verified wild-type and phosphomimetic mutant proteins for post-translational modification analysis. |
| Lack of Controls | Sequence-validated benchmark antibodies and target-specific siRNA pools included for assay calibration. |
| False Positives in Cell Assays | Lentiviral vectors with native promoters to ensure physiologically relevant expression levels. |
Live IRF7 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
"The race for IRF7 therapeutics is intensifying, with major players shifting focus from traditional systemic interferon blockade to precise intracellular modulation. As first-generation upstream pathway inhibitors (such as TLR7/8/9 antagonists) advance in clinical trials for systemic lupus erythematosus (SLE), the next wave of R&D is targeting direct IRF7 modulation to achieve cell-type specific immunosuppression or selective immuno-oncology activation."
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Biogen, Merck KGaA, Bristol Myers Squibb | Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome | High-throughput screening assays utilizing purified, biologically active IRF7 proteins. |
| Small Molecule Agonists | Immuno-Oncology Biotechs | Solid Tumors (Cold Tumors) | STING-IRF7 pathway activation validation requiring lentiviral reporter cell lines. |
| RNA Therapeutics (siRNA/ASO) | Alnylam, Ionis Pharmaceuticals | Autoimmune Diseases, Viral Infections | In vitro knockdown validation using validated siRNA and quantitative qPCR controls. |